Levels of 17β-hydroxysteroid dehydrogenase type 10 in CSF are not a valuable biomarker for multiple sclerosis

Aim: We aimed to characterize the role of mitochondrial 17 beta-hydroxysteroid dehydrogenase type 10 (17 beta-HSD10) overexpression in multiple sclerosis (MS) and to evaluate its use as a biomarker. Materials & methods: We estimated levels of 17 beta -HSD10, amyloid beta 1-42, cyclophilin D, 17 beta-HSD10-cyclophilin D complexes or 17 beta-HSD10-parkin complexes in cerebrospinal fluid (CSF) samples. Results: The increase in 17 beta-HSD10 levels or in 17 beta-HSD10-parkin complexes and links to leukocytes were found only in relapsing-remitting MS. The sensitivity of the biomarker was 64%, the specificity equaled 60-63% compared with controls. Conclusion: Increased CSF levels of 17 beta-HSD10 in later stages of MS could be interpreted via its upregulation in demyelinated neuronal axons. CSF levels of 17 beta-HSD10 are not the valuable biomarker for the early diagnosis or for the progression of MS.